Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MyHealthChecked PLC ( (GB:MHC) ) has shared an announcement.
MyHealthChecked PLC reported a significant decrease in revenue for 2024, down to £3.6 million from £11.0 million in 2023, alongside an increased EBITDA loss. Despite the decline in COVID LFT sales, the company saw a 92% increase in wellness test sales, highlighting potential growth in this segment. The company has strengthened its strategic relationship with Boots and expanded its product portfolio with new tests like the Heart Health self-test. MyHealthChecked aims to leverage its digital platform to enhance customer engagement and explore further partnerships, positioning itself for long-term growth in the consumer wellness market.
More about MyHealthChecked PLC
MyHealthChecked PLC, based in Cardiff, is a UK healthcare company listed on AIM, specializing in at-home healthcare and wellness tests. The company offers a range of rapid tests and sample collection kits for DNA, RNA, and blood, available online and over-the-counter, focusing on accessible healthcare solutions.
Average Trading Volume: 26,142
Technical Sentiment Signal: Sell
Current Market Cap: £5.57M
For detailed information about MHC stock, go to TipRanks’ Stock Analysis page.